Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The Biomarkers Consortium

Nature Reviews Drug Discovery volume 13, pages 791–792 (2014)Cite this article

Subjects

The Biomarkers Consortium is a public–private biomedical research partnership that seeks to develop and qualify biomarkers across a broad range of diseases in order to accelerate the development of new medicines and improve patient care.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Talbot, G. H. et al. on behalf of the CABP-ABSSSI Project Team. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin. Infect. Dis. 55, 1114–1121 (2012).

    Article  Google Scholar 

  2. File, T. M. Jr et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin. Infect. Dis. 51, 1395–1405 (2010).

    Article  CAS  Google Scholar 

  3. Boucher, H. W. et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N. Engl. J. Med. 370, 2169–2179 (2014).

    Article  Google Scholar 

  4. Esserman, L. J. & Woodcock, J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 306, 2608–2609 (2011).

    Article  CAS  Google Scholar 

  5. Prowell, T. M. & Pazdur, R. Pathological complete response and accelerated drug approval in early breast cancer. N. Engl. J. Med. 366, 2438–2441 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Foundation for the National Institutes of Health, Bethesda, 20814, Maryland, USA

    David Wholley

Authors
  1. David Wholley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Wholley.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Supplementary information

Supplementary information S1 (table)

Biomarkers Consortium Membership (PDF 134 kb)

Supplementary information S2 (table)

Summary of Biomarkers Consortium Projects (PDF 111 kb)

Related links

Related links

FURTHER INFORMATION

Biomarkers Consortium

Foundation for the National Institutes of Health

US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry community-acquired bacterial pneumonia: developing drugs for treatment (HFA-305)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wholley, D. The Biomarkers Consortium. Nat Rev Drug Discov 13, 791–792 (2014). https://doi.org/10.1038/nrd4439

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4439

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research